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Background:  In August  and  September  2014,  unexpected  clusters  of enterovirus-D68  (EV-D68)  infections
associated  with  severe  respiratory  disease  emerged  from  North-America.  In September,  the  European
Centre  for  Disease  Prevention  and  Control  (ECDC)  asked  European  countries  to strengthen  respiratory
sample  screening  for  enterovirus  detection  and  typing  in  cases  with  severe  respiratory  presentations.
Objectives:  To provide  a  detailed  picture  of EV-D68  epidemiology  in  Europe  by  conducting  a  retrospective
and  prospective  laboratory  analysis  of  clinical  specimens.
Study  design:  An  initiative  supported  by the  European  Society  for Clinical  Virology  (ESCV)  and  ECDC  was
launched  to  screen  for  EV-D68  in  respiratory  specimens  between  July  1st and  December  1st  2014  in
Europe  and  to sequence  the  VP1  region  of detected  viruses  for phylogenetic  analytic  purposes.
Results:  Forty-two  institutes,  representing  51  laboratories  from  17  European  countries,  analyzed  17,248
specimens  yielding  389 EV-D68  positive  samples  (2.26%)  in  14 countries.  The  proportion  of  positive
samples  ranged  between  0 and  25%  per country.  These  infections  resulted  primarily  in  mild  respira-
tory  disease,  mainly  detected  in young  children  presenting  with  wheezing  and  in  immuno-compromised
adults.  The  viruses  detected  in Europe  are  genetically  very  similar  to  those  of  the  North-American  epi-
demic  and  the  majority  (83%)  could  be  assigned  to clade  B.  Except  for 3 acute  ﬂaccid  paralysis  (AFP)  cases,
one  death  and  limited  ICU admissions,  no severe  cases  were  reported.
Conclusions:  The  European  study  showed  that  EV-D68  circulated  in Europe  during  summer  and  fall  of
2014 with  a moderate  disease  burden  and different  pathogenic  proﬁle  compared  to  the North-American
epidemic.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Enterovirus D68 (EV-D68), formerly classiﬁed as rhinovirus 87
(RV-87) [14], has a mixture of enterovirus (EV) and rhinovirus (RV)
features and can induce severe respiratory symptoms, mostly in
children [15,16]. In addition, it has been detected in respiratory
samples from patients who developed acute ﬂaccid paralysis (AFP)
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or acute ﬂaccid myelitis [12], but no deﬁnite link between EV-D68
infection and neurological disease has yet been established [13].
To date, EV-D68 has never posed a serious threat to the general
public health [7–11]. Only limited clusters (in magnitude and in
geographic distribution) have been reported in different regions of
the world. In most of these instances, the virus was detected in less
than 10% of the EV or RV-related reported cases, and was  typically
co-circulating with other rhinoviruses or enteroviruses [17–21].
Though, between mid-August and December 2014, an apparent
upsurge of severe respiratory tract infections was observed in the
United States and Canada, especially among children with under-
lying chronic pulmonary illness presenting to hospital emergency
departments [1–3]. Health authorities in 49 States and the District
of Columbia reported 1153 cases of laboratory-conﬁrmed EV-D68
infections by the 15th of January 2015, including 14 fatal cases
in young children, and several severe neurological presentations
http://dx.doi.org/10.1016/j.jcv.2015.07.296
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
2 R. Poelman et al. / Journal of Clinical Virology 71 (2015) 1–9
(cdc.gov/non-polio-enterovirus/about/ev-d68.html#outbreak). At
the same time, though two European countries reported the
circulation of this respiratory virus, no further upsurge of
severe respiratory tract infections was reported in Europe
([4–6], ecdc.europa.eu/en/publications/Publications/Enterovirus-
D68-United-States-Canada.pdf).
Arguably, EV-D68 infections are insufﬁciently detected owing
to a lack of targeted viral diagnostics and clinical awareness [10].
The EV surveillance carried out in Europe, North America and other
parts of the world, provides limited information on EV-related
respiratory illness. The focus for the worldwide EV surveillance
network is primarily on neurological presentation (such as AFP),
to support poliovirus eradication programmes. The monitoring of
respiratory diseases, carried out by for instance inﬂuenza surveil-
lance networks by using pathogen-speciﬁc PCRs, is mainly directed
towards inﬂuenza virus and respiratory syncytial virus during win-
ter. In addition, most hospital-based laboratories are using PCR
detection methods which target RV, and may  fail to detect EV types
[22]. Thus, most of the diagnostic tools used for respiratory virus
detection in either in- or out-patients may  not detect respiratory
EV and, when an RV or an EV is detected by generic PCR assays, no
discrimination between these two groups is possible such that the
detected viruses are frequently not genotyped. In addition, infor-
mation about circulating rhinovirus genotypes has been scarcely
documented ([23,24], B. Lina personal communication).
2. Objectives
In order to provide a detailed picture of the EV-D68 circula-
tion in Europe, we conducted a European-wide retrospective and
prospective laboratory analysis of clinical specimens between July
and December 2014, in collaboration with the European Society
for Clinical Virology (ESCV) and the European Centre for Disease
Prevention and Control (ECDC).
3. Study design
3.1. Enrolment of the laboratories
An ad hoc meeting was held at the annual ESCV conference in
Prague (end of September 2014), to launch the European EV-D68
network. Subsequently, the ESCV board invited the members of
the scientiﬁc community to join this initiative. The ECDC agreed to
support in early October and invited all European Union/European
Economic Area member states to participate through National
Microbiology Focal Points. These efforts resulted in the involve-
ment of a large number of participating laboratories. Also, Quality
Control for Molecular Diagnostics was involved as External Quality
Assessment Program organization (QCMD EQA, Glasgow, United
Kingdom), providing data on performances of commercial assays
and laboratory developed tests (LDT’s). Forty-two European insti-
tutes which represent a total of 51 laboratories from 17 countries
(Wales and Scotland representing the United Kingdom) responded
to this ESCV/ECDC EV-D68 initiative, of which 35 provided the full
set of data (number of specimens received, number of RV-EV posi-
tives and number of EV-D68 positives, Table 1). Seven laboratories
provided the number of RV-EV positives and number of EV-D68
positives only.
3.2. Detection of EV-D68 in specimens throughout Europe
In September 2014, each participating laboratory was asked to
test their respiratory specimens collected between the 1st of July
and 1st of December 2014 from children younger than 16 years
of age admitted to or visiting the hospital with any respiratory
symptoms. Where possible, laboratories were permitted to
broaden their retrospective surveillance to before July 1st (i.e.,
January 2014) and to include samples from adults. Full reporting
of the results also had to be completed by December 1st, 2014.
For the rapid detection of EV-D68, a speciﬁc real-time PCR was
developed and proposed by the laboratory in Groningen (NLD) [4].
Each laboratory could use this speciﬁc PCR as needed.
3.3. Sequencing of EV-D68 VP1 in positive specimens and
sequence analysis
Participating laboratories carried out the partial sequencing
of VP1 of either EV-D68 positive or EV/RV positive samples as
described by Nix et al. [25]. The ∼350 to 400 base pairs VP1 par-
tial sequences obtained were assigned to EV-D68 clades according
to Tokarz et al. [26]. Where needed, laboratories could send their
material to the Groningen or Lyon laboratories for sequencing.
Sequence data were analyzed with Sequencing Analysis (ver-
sion 5.3; ABI) using BioNumerics Software 6.6 (Applied Maths,
Sint-Martens-Latem, Belgium). Phylogenetic trees (maximum
parsimony) were obtained according to BioNumerics standard pro-
cedures.
The sequences obtained from the network were aligned using
ClustalW in MEGA5 and compared using R bioconductor. Raw
distances between pair-wise sequences were calculated using
pair-wise deletion method. Amino acids that differentiate each
genogroup were deﬁned using custom scripts. Many of the available
sequences were deposited in GenBank. The accession numbers are
as follows: Denmark (KP729103–KP729109), Finland (KP728259)
France (LN626610; LN681316–330; KP196362–378; KP307990;
KP406467–496), Germany (KP745729–43), Ireland (KP739245),
Italy (KP153538–KP153546), Netherlands (KM887894–
KM887906/KM924544–KM924547/KM975346–KM975350/
KM975330–KM975335/KP830119–128/KP830131–135), Norway
(KP744824–KP744839), Spain (KP090456–KP090459/KP122208),
Sweden (KP745744–50).
3.4. Collection of clinical data
In addition to the number of specimens processed for this
study, each laboratory was asked to provide the number of EV- or
RV-detected in-respiratory specimens and the number of EV-D68
positives amongst these specimens.
For the EV-D68 positive cases, the laboratories provided the
clinical information blindly, wherever possible, by ﬁlling in a short
predeﬁned questionnaire. Speciﬁcally, participants were requested
to report the date of specimen collection, age of the patients, clini-
cal presentation (respiratory illness or other), underlying condition
(i.e. chronic respiratory conditions, immuno-compromised status),
and admission status (inpatient or outpatient; hospital admission
and/or admission to the Intensive Care Unit).
3.5. Evaluation of the diagnostic tools used in Europe
Current methods that are used by the participating laboratories
for the detection of EV-D68 were assessed. Each laboratory was
requested to perform an in silico evaluation of its EV/RV diagnostic
procedure for the detection of EV-D68. For this purpose, a sample
of the Fermon reference strain was  provided by the French National
Enterovirus Reference Laboratory to allow laboratories to test the
accuracy of their EV or EV/RV assays. Moreover, QCMD-registered
laboratories could obtain information on their capacity to detect
EV-D68 (this virus being speciﬁcally present in the recent EV (2013)
and RV (2014) EQA panels.
QCMD has generously provided the performance evaluation
sheet of the different techniques used by the participants to the
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Table  1
European EV-D68 detection data by country and laboratory in Europe (July 1st–December 1st 2014), including 916 specimens from a non-screening strategy.
Country Lab and/or city Tested EV Genus (=EV
and/or HRV)
EV-D68 Total/Country EV68/EV
Genus (%)
Norway Oslo NIPH 66 25 9
Oslo  Ullevål 354 71 34
Trondheim 157 101 6 49 24.9%
Sweden Stockholm Karolinska/PHI/ 30a 30 7 7 23.3%
Finland Turku UTU 700 140 10
Helsinki HUS 109 15 4
Helsinki THL 91 29 3 17 9.2%
Scotland Glasgow 488a 488 22 22 4.5%
Ireland NVRL Dublin 1010 51 4 4 7.8%
Wales  Cardiff NHS 604 62 9 9 14.5%
Netherlands Erasmus MC  Rotterdam 198 46 7
Leiden UMC  780 185 3
Radboud UMC  270 6 1
Regional health service Haarlem 252 62 4
UMC  Groningen 2397 531 19
RIVM Bilthoven NIH 370 130 22 56 5.8%
Denmark Statens serum institut SSI 252 50 8 8 16.0%
Germany Bonn 351 35 1
Freiburg 136a 136 6
Berlin, Robert Koch Institutc 1658 58 15
Leipzig, Institute of Virology 364 93 9 31 9.6%
Poland Warsaw NIH 144 22 0 0
Romenia Bucharest 56 0 0 0
Austria Vienna 778 47 1 1 2.1%
Slovenia Ljubljana 702 234 48 48 20.5%
Italy  Milan 176 97 4
Pavia  195a 195 9 13 4.5%
Luxembourg Luxembourg 19a 19 1 1 5.3%
France Lyon/Nat ref centre EV 1589 439 39
Clermont-Ferrand/Nat ref centre EV 710 191 25
Brest 199 86 9
Caen  367 175 22
Dijon 159 37 5
Paris  49 25 0
Saint-Etienne 104 36 6
Strasbourg 203 102 9
Versailles 109 34 2 117 10.4%
Spain  Barcelona 529 53 5
Valencia 458 89 0
Santander 15a 15 0
Valladolid 33a 33 1 6 3.2%
Portugal Lisbon 17 0 0 0
Total  number of countriesb Total number of labs
17 42 17,248 4273 389
a Non-screening strategy.
b Wales and Scotland representing the United Kingdom.
c Includes three laboratories from: Dusseldorf, Heidelberg and Wurzburg.
EV QCMD Quality Control panel. This information was correlated
with the in silico self-evaluation provided by the participating labs.
3.6. Statistical analysis
Statistical analysis was performed by using the Chi-Square Test
(CI 95%) and Fisher’s exact test (p-value < 0.05).
4. Results
4.1. EV-D68 detection and distribution in Europe
A total of 17,248 (mostly respiratory) samples were tested,
mainly collected between the 1st of July and the 1st of December
(Table 1). Overall, a picornavirus (EV or RV) was  detected in 4273
specimens, of which 389 were identiﬁed as EV-D68. The Euro-
pean mean EV/RV positivity rate (calculated from the 35 labs) in
respiratory specimens was 20.5% (3357/16,332), of which 10.21%
(343/3357) were EV-D68 positive, yielding an EV-D68 positivity
rate of 2.1% (343/16,332) in respiratory samples.
The virus was detected in each participating country across
Europe, except for three: Poland, Portugal and Romania; but in
these countries only a limited number of samples were tested. The
proportion of EV-D68 positive samples among the total number
of respiratory samples tested differed between countries, ranging
from 0% to 25% (Table 1, Fig. 1). EV-D68 was  detected throughout
the ﬁve months of the study, with a peak in October and a clear
4 R. Poelman et al. / Journal of Clinical Virology 71 (2015) 1–9
Fig. 1. European detection rates of EV-D68 by participating countries, in Europe,
2014. Colour codes: white non-data, White with a star: no detection, light grey:
1–5%; grey: 5–15%; dark grey 15–25%.
epidemic trend (Fig. 2). A North–South gradient was observed with
a higher level of detection in Northern (Norway, Sweden, Denmark)
than in Southern European countries (Italy, Spain, Portugal; Fig. 1;
Table 1). Only 6 cases were detected in Spain, 13 in Italy and none
in Portugal.
4.2. Sequencing
Of the 389 EV-D68 strains that were detected, 205 (52.7%) were
sequenced and subsequently assigned to the subgroups described
by Tokarz et al. [26]. All the EV-D68 viruses belonged to clades
A (n = 35; 17.1%) and B (n = 170; 82.9%); no clade C virus has
been detected. Viruses from the clades A and B were co-detected
in 12 countries, while Spain reported only clade A viruses and
Slovenia and Norway only clade B viruses. The Blast analysis and
the maximum parsimony tree show high nucleotide homology
between the US and European viruses (Fig. 3, Suppl. Figure 1).
Identical sequences were obtained from viruses detected in dif-
ferent countries (Fig. 3, Suppl. Figure 1). Both ﬁgures show a
segregation of the clade A viruses into two sub-clusters, A1 (n = 11;
31.4%) and A2 (n = 24; 68.6%) with an average raw nucleotide dis-
tance of 11% between the two  sub-clusters (Fig. 3). The signiﬁcance
of this segregation needs to be conﬁrmed by further Bayesian anal-
ysis. The nucleotide divergence between the whole clade A and
clade B was  13.8%. All 2014 VP1 sequences of clade A viruses had
a deletion of one amino acid in position 140, while 9 other amino-
acids could differentiate at least one clade from another (Suppl.
Table 1). More than 30 amino acids at the end of the VP1 coding
sequence were found to be speciﬁc to the 2014 sequences when
compared to previous sequences (data not shown). These changes
are observed in regions where neither the impact on the immuno-
genicity of the virus nor that on binding to sialic acids was known
[27]. Finally, there were no absolute differences in the BC and DE
loops of VP1 between the US and the European 2014 viruses (Suppl.
Table 2). However, when comparing the frequencies of amino-acids
at each position, two positions in the BC and DE loops, at residues 97
and 143, respectively, showed signiﬁcant differences between the
USA and European strains in Clade B (Fisher’s exact test; p < 0.05).
As there were only a few viral sequences from the USA outbreak,
further analysis must be done before it can be concluded that the
strains circulating in the USA and Europe in 2014 were differ-
ent. Such a comparison could not be performed for viruses of the
sub-clade A1 for which no sequence from the USA outbreak was
available.
Supplementary Fig. 1, Tables 1 and 2 related to this article can
be found, in the online version, at http://dx.doi.org/10.1016/j.jcv.
2015.07.296
4.3. Clinical analysis
EV-D68 was  detected in all age groups (Table 2). From the
389 documented cases, three AFP cases (two in Norway and one
in France) and one death, of a 14-year-old Italian patient with
severe neurological underlying disease, have already been reported
[40]. Underlying conditions that predisposes to the development
of severe respiratory infections were frequent in all age groups
(Table 2, Suppl. Table 3). Data on underlying conditions were
Fig. 2. Epidemiological curve of EV-D68 detection in European countries participating in the study by sampling date, 2014. 17 samples are not included in this graph, due to
a  lack of sampling date. Colour code: Green = clade A: Blue = clade B, Red = clade not assigned.
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Fig. 3. Maximum Parsimony tree of partial VP1 sequences of EV-D68. Sequences from 205 EV-D68 positive specimens, all detected in 2014, are included. Identical sequences
are  merged in the bigger nodes. Colour codes for each country are the same as for Fig. 3 and Suppl. Figure 1. Clades are according to Tokarz et al. [26].
available in only 91/120 (76%) children below the age of 2. Of
these 20/91 (21.9%) had chronic or recurrent respiratory prob-
lems, 10 (11%) had other underlying disease, 3 (3.3%) where
immuno-compromised, whereas the majority (58/91; 63.7%) did
not have any recognized underlying disease (Table 2, Suppl. Table
3). In the age group 2–5 years information was missing from 63 indi-
viduals (46.7%). When documented, 44/72 (61.1%) were known to
have underlying conditions, the largest group having a chronic or
recurrent pulmonary disease (n = 27/72, 37.5%). In 197 documented
children of all age groups (<17), immuno-compromised conditions
were present in only 8 of EV-D68 cases (4.1%). This was  differ-
ent for the adults (>17) in question, where immuno-compromised
patients (following transplantation or cancer treatment) formed a
signiﬁcantly larger proportion of the cohort than with the children
(37.5% vs 4.1%; p < 0.001; Chi-square test). Nonetheless, although
the difference is not signiﬁcant, only 9/45 documented adults (20%)
had underlying chronic respiratory diseases as compared to 63/197
documented children (32%).
Supplementary Table 3 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jcv.2015.07.296
In the four age groups, similar proportions of patients admitted
to the ICU amongst the hospitalized cases were observed (15/110,
11/121, 5/45 and 3/38 for 0–1 year, 2–5 year, 6–16 and 17 and
over, respectively). None of the clades was associated with clinical
severity or age-distribution.
4.4. Performance of commercial test kits and (speciﬁc) real-time
PCR
Overall, 29 laboratories used LDT’s, 18 used commercial assays
and 3 used both in-house and commercial assays. One  labo-
ratory did not provide details of the assay used. Brieﬂy, the
retrospective analysis of the performance of the commercially
available kits conﬁrmed that the SEEGENE Anyplex II RV16
detection assay (Korea) that is used by two laboratories did
not detect EV-D68, while this assay preferentially targeting
only EV. The Cepheid Smartcycler (Cepheid, Sunnyvale, USA),
the Fast-Track Diagnostics (Sliema, Malta) and the Diagenode
human EV test (Liege, Belgium), did detect EV-D68. In addi-
tion, the most commonly used commercial assays, such as the
xTAG Respiratory Viral Panel (Luminex Europe, Den Bosch, The
Netherlands) Respiﬁnder Smart 22 fast v2 (Pathoﬁnder, Maastricht,
The Netherlands), Rhino&Entero/Ccr-gene (bioMerieux/Argene,
Marcy l’Etoile, France), were not able to discriminate between RV
Table 2
Underlying diseases categories in EV-D68-positive cases by age group in the 14 EU/EEA countries (July 1st–December 1st 2014).
Age EV68 positive Underlying disease
Chronic respiratory illness Immunocompromised Non-respiratory illness None Not assigned
0–1 120 20 (16.7%) 3 (2.5%) 10 (8.3%) 58 (48.3%) 29 (24.2%)
2–5  135 27 (20.0%) 5 (3.7%) 12 (8.9%) 28 (20.7%) 63 (46.7%)
6–16 56 16 (28.6%) 1 (1.8%) 6 (10.7%) 11 (19.6%) 22 (39.3%)
≥17  78 9 (11.5%) 17 (21.8%) 5 (6.4%) 14 (17.9%) 33 (42.3%)
Total  389 72 (18.5%) 26 (6.7%) 33 (8.5%) 111 (28.5%) 147 (37.8%)
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and EV, but detected EV-68. Speciﬁc mentioning that such kits may
or may  not detect EV-D68 is not included in their product informa-
tion insert, but testing the Fermon strain did indicate the detection
potential of some of these assays. Besides, a total of 31 laboratories
implemented one of the available speciﬁc EV-D68 real-time PCR’s
[4,6].
5. Discussion
Between 1963 and 2014, EV-D68 upsurges involving children
with underlying respiratory diseases have been reported in dif-
ferent countries, albeit with a quite limited number of cases
[8,18,28,29]. In contrast to the rapidly accumulating EV-D68 cases
observed in North America in 2014 [1,11], no sudden increase
of EV-D68 was reported in Europe, except for Norway and the
Netherlands [4–6]. The initiative launched by the European Society
for Clinical Virology (ESCV) and supported by the European Centre
for Disease prevention and Control (ECDC) was primarily aimed at
a rapid European-wide screening for the detection of the possibly
emerging EV-D68.
Following the launch of the initiative, EV-D68 detection
protocols were formulated and implemented to screen 17,248
respiratory specimens collected between July and November
2014, allowing a rapid response within a two-month period
(October–December 2014). EV-D68 was detected in all participat-
ing countries, except for three (Fig. 1, Table 1), though two  analyzed
a limited number of specimens (17 and 56, respectively) and the
other used an assay which may  have been the cause for missing
(a low level of circulation of) the virus. The 2014 instance was the
largest European EV-D68 epidemic described since the isolation of
the Fermon strain in 1962.
The trend of detection (though somewhat biased by the imple-
mentation of the survey itself) showed a clear epidemic curve, with
a peak of cases in October (Fig. 2) and local epidemics reported
[4–6]. The number of cases diminished in December, as would be
expected for an EV epidemic, particularly where RSV and inﬂuenza
epidemics come into play [30].
A European North–South gradient was observed, revealing dis-
crepancies in the levels of virus detection. In some instances,
discrepancies were observed between laboratories in the same
country (Table 1). This could be partly explained by local epidemics
or clusters (as in Norway and Slovenia) or by local differences
in testing periods (the Netherlands). This divergence in observed
results raised questions about the capacity of some assays to detect
EV-D68. Thanks to the recent EV-RV EQA panels provided by QCMD,
which included EV-D68, we could conﬁrm that most of the partici-
pating laboratories used kits appropriate for EV-D68 detection. This
was further attested when they used the EV-D68-speciﬁc detec-
tion protocols. However, a few laboratories did not; the Seegene
Anyplex II RV16 detection assay® failed to detect EV-D68.
Still, relatively few clinical diagnostic laboratories employ
systematic EV detection followed by genotyping in the rou-
tine screening strategy of respiratory materials, both in Europe
and the USA [11,16,29]. Hence, clusters of EV infections may
remain undocumented until a signiﬁcant EV-related clinical burden
arises.
The clinical picture that we describe is a reﬂection of the
underlying hospitalized population, rather than a representation
of the community or of the primary healthcare level. Consistently
about 10% of the cases in all age groups required intensive care
respiratory support. Of the EV-D68 cases recorded in our study, pre-
existing respiratory conditions were frequent in young children,
whereas underlying immune-compromising conditions were fre-
quent in adults (Table 2). This ﬁnding has been reported elsewhere
[31].
In contrast to the USA, only one death was reported in Europe
during this EV-D68 survey and only 3 children were diagnosed with
EV-D68 related AFP [2,6,36]. This difference in clinical impact was
also noted in the recent retrospective study conducted in the USA.
Greninger et al. reported that EV-D68 of clade B similar to those
detected in the European survey was  frequently detected in the
respiratory secretions of patients with acute ﬂaccid myelitis [12].
No such cases have been observed in Europe to date. This absence
is not attributable either to a lack of detection capabilities or of
appropriate sample collection. Indeed, most European countries
have active surveillance programmes for poliovirus infections in
which EV-associated neurological presentations are reported and
documented by reference laboratories [22]. Three cases of EV-D68
related AFP have been reported (two in Norway and one in France),
showing the capacity of the system to detect AFP-related cases [36].
Even if no link is established between AFP and EV-D68 infection,
more surveillance is needed to better assess its putative role in
severe neurological presentations [12,13,37].
As part of our study, 205 isolates were sequenced to investi-
gate their relationship with the circulating EV-D68 virus types in
North America and to determine if severity could be correlated to
a given clade of the virus [26]. Our sequence data conﬁrms that A
and B clades were circulating, just as in the USA and Canada [2].
The European and North American EV-D68 viruses were geneti-
cally closely related, but a speciﬁc virus genetic signature was  not
associated with virulence.
EV-D68 can be easily transmitted through droplets and is the
most frequently encountered group D EV (although this is a small
group) [11,14,15]. It has been demonstrated that this virus binds
to the sialic acid 2,6, as do other respiratory viruses, as a result of
adaptations in the BC and DE loops of the VP1 capsid region [27].
Despite ongoing research, there is no antiviral treatment available
[32,33]. However, Lui et al. recently suggested that Pleconaril could
be effective in treating the latest EV-D68 infections because of its
excellent binding into the hydrophobic canyon of the capsid; this
canyon being narrower than those in most other RVs and EVs [34].
Though this drug is not commercially available, it may  be useful
to evaluate its contribution to the management of severe EV-D68
infections, and the alleviation of outbreaks such as those occurring
in nursing homes [24,35].
However, more sequences from the US outbreak are required
to determine whether speciﬁc residues in the BC and DE loops of
VP1 might have different amino acid proportions in US versus Euro-
pean sequences [2]. Despite this apparent lack of difference in the
severity of the diseases, some evolution was  observed in the BC loop
which reinforces the argument in favour of distinguishing between
clades A and B [38,39].
In conclusion, this collaborative venture highlights the merits
of working together on cross-border studies of infectious disease
epidemics using established networks. A timely response is essen-
tial to evaluate the circulation and relevance of an emerging virus.
Therefore the global or at least continental networks, such as the
ECDC and ESCV could provide, need to be equipped to facilitate
and streamline proper procedures for a rapid and efﬁcient handling
of an emerging virus, whenever it occurs. Additionally, long-term
studies are needed to adequately collect clinical data for a better
understanding of the pathogenesis.
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